Log in to your Inderes Free account to see all free content on this page.

FluoGuide

34.25

SEK

-1.72 %

FLUO

First North Stockholm

Medical Equipment & Services

Health Care

7 following

-1.72%

-13.29%

-15.01%

-29.38%

-44.04%

-53.59%

-61.34%

+359.82%

+282.03%

fluoguide.com/investor/share-information

FluoGuide is a Danish company active in medical technology. The company's business focus is found in research and development of treatments against various forms of cancer, with the greatest focus on the development of products that guide surgical interventions. The products bind to the cancer cells, which then light up and are intended to be used to precisely remove harmful tumors in the patient's tissue.

Revenue

-

EBIT %

-

P/E

-

Dividend yield-%

-

Target price

-

Recommendation

-

Updated

-

First North Stockholm

FLUO

Daily low / high price

34.25 / 35.9 SEK

Market cap

466.49M SEK

Turnover

309.94K SEK

Volume

8.9K

Latest videos

Introduction to FluoGuide

Financial calendar

Interim report

27.11.2024

Annual report

27.02.2025

Major Owners
Source: Millistream Market Data AB

Owner	Capital	Votes
Life Science IVS	17.4 %	17.4 %
Wexotec ApS	12.2 %	12.2 %

Premium

This content is for our Premium customers only.

Login in to make your own estimates and see other investors estimates.

ShowingAll content types

Press release11/19/2024, 12:43 PM

Publication of positive phase II clinical data for FG001 in patients with head and neck cancer

Regulatory press release11/12/2024, 5:23 PM

FluoGuide A/S issue warrants to board member, CMO and CFO

Press release10/21/2024, 2:13 PM

Roger Gunnarsson resigns as board member due to return to a full-time investment banking career, which precludes him from holding board position in FluoGuide

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Press release10/7/2024, 11:13 AM

FluoGuide A/S submits Clinical Trial Application for phase II trial in head and neck cancer

Press release8/29/2024, 5:19 PM

Redeye: Fluoguide Q2 2024 - Following the plan

Regulatory press release8/29/2024, 6:55 AM

FluoGuide A/S publishes interim report for the period January – June 2024

Regulatory press release8/26/2024, 7:05 AM

FluoGuide appoints Jens Ellrich as Chief Medical Officer

Regulatory press release6/18/2024, 9:12 PM

FluoGuide has completed a directed share issue to existing and new investors raising proceeds of SEK 60 million

Regulatory press release6/18/2024, 3:31 PM

FluoGuide intends to carry out a directed share issue of approximately SEK 60 million

Press release5/30/2024, 2:51 PM

Redeye: Fluoguide Q1 2024 - Preparing for next steps

Regulatory press release5/30/2024, 6:51 AM

FluoGuide A/S publishes interim report for the period January – March 2024

Press release5/27/2024, 7:40 AM

FluoGuide selects laser system for photothermal cancer therapy with FG001

Fluoguide: Wrap up from interview with CEO Morten Albrechtsen

Analyst Comment3/21/2024, 7:30 AM by

Fluoguide: Wrap up from interview with CEO Morten Albrechtsen

Dive into the company's latest partnership with Intuitive Surgical and how the partnership looks like for Fluoguide.

Regulatory press release3/20/2024, 1:25 PM

Minutes from Annual General Meeting in FluoGuide A/S

HCA Biosnack update: Biotech and Life Science stocks outperform as the general stock market moves to record highs.

Analyst Comment3/14/2024, 8:36 AM by

Henrik Ekman, Philip Coombes, Claus Thestrup

HCA Biosnack update: Biotech and Life Science stocks outperform as the general stock market moves to record highs.

After a slow start to 2024, February and the beginning of March turned out to be a very strong period for Biotech and Life Science stocks as illustrated above. Even more so, if measured since late October 2023. Looking at 2024, the general S&P Biotech index is now up 7.7 percent year-to-date, outperforming MSCI World All Countries which is up 7.0 percent. Nordic focused HCA Little Mermaid index is up 6.0 percent.

Ascelia Pharma BioPorto Curasight ExpreS2ion Biotech Holding FluoGuide NeoDynamics Pharma Equity Group Qlife Holding

Regulatory press release3/13/2024, 10:17 AM

Chief Financial Officer (CFO) Ole Larsen buys shares

Regulatory press release3/12/2024, 11:12 AM

FluoGuide enters collaboration within robot assisted head and neck cancer surgery with Intuitive Surgical, a world leading robotic-assisted surgery company

Fluoguide: Wrap up from introduction to the company

Analyst Comment3/5/2024, 12:18 PM by

Henrik Ekman, Claus Thestrup

Fluoguide: Wrap up from introduction to the company

Interview with CEO Morten Albrechtsen about the pipeline and opportunities

Regulatory press release3/1/2024, 11:41 AM

Notice of Annual General Meeting in FluoGuide A/S

Press release2/28/2024, 1:20 PM

Redeye: Fluoguide Q4 2023 - Bright prospects